{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:38:09Z","timestamp":1787312289314,"version":"build-2736575974"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Key Project of Jiangxi Provincial Nature Science Foundation","award":["20224ACB206008"],"award-info":[{"award-number":["20224ACB206008"]}]},{"DOI":"10.13039\/501100010871","name":"Thousand Talents Plan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Project of Introducing and Training High-Level Talents of Innovation and Entrepreneurship in Jiangxi Province","award":["JXSQ2023201030"],"award-info":[{"award-number":["JXSQ2023201030"]}]},{"name":"Jiangxi Province Key Laboratory of Molecular Medicine","award":["2024SSY06231"],"award-info":[{"award-number":["2024SSY06231"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,31]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To investigate the efficacy and safety of telitacicept in adult immunoglobulin A vasculitis nephritis (IgAVN) patients with persistent proteinuria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective single-arm study enrolled patients aged \u226518\u00a0years diagnosed with IgAVN, an estimated glomerular filtration rate &amp;gt;60\u00a0mL\/min\/1.73 m2, previously received previous treatment with corticosteroids and immunosuppressants or had contraindications to the use of corticosteroids and immunosuppressants, and a 24-h urinary protein\u2013creatinine ratio (UPCR) &amp;gt;1\u00a0g\/g. Patients received telitacicept 160\u00a0mg weekly for 6\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 13 patients were enrolled in this study, of which 7 were males. The mean age of patients was 35\u00a0years. The mean time since diagnosis before telitacicept treatment was 12.6\u00a0months. After 6\u00a0months of treatment with telitacicept, the mean 24-h UPCR decreased from a baseline value of 2.9\u00a0\u00b1\u00a00.8 to 0.5\u00a0\u00b1\u00a00.3\u00a0g\/g (P\u00a0&amp;lt;\u00a0.001). At 9\u00a0months, 12 patients (92.3%) achieved complete remission, and the mean 24-h UPCR decreased to 0.4\u00a0\u00b1\u00a00.1\u00a0g\/g. Additionally, the renal function of patients remained stable, urinary red blood cells, blood CD4+ T cells, CD19+ B cells, immunoglobulin levels were decreased compared with the baseline values in all patients at 9\u00a0months (P\u00a0&amp;lt;\u00a0.05). No severe adverse events were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Additional telitacicept significantly increased the complete remission rate of IgAVN with persistent proteinuria and stabilized renal function, without serious adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfaf210","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T11:51:09Z","timestamp":1759578669000},"page":"786-792","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of telitacicept in adult IgA vasculitis nephropathy"],"prefix":"10.1093","volume":"41","author":[{"given":"Ran","family":"Zhang","sequence":"first","affiliation":[{"name":"The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University Department of Nephrology, , Nanchang ,","place":["P. R. China"]},{"name":"Jiangxi Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University , Nanchang ,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University Department of Nephrology, , Nanchang ,","place":["P. R. China"]},{"name":"Jiangxi Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University , Nanchang ,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zeng","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University Department of Nephrology, , Nanchang ,","place":["P. R. China"]},{"name":"Jiangxi Key Laboratory of Molecular Medicine, The Second Affiliated Hospital of Nanchang University , Nanchang ,","place":["P. R. China"]},{"name":"Ganzhou People\u2019s Hospital Department of Nephrology, , Ganzhou ,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehui","family":"Liu","sequence":"additional","affiliation":[{"name":"Ganzhou People\u2019s Hospital Department of Nephrology, , Ganzhou ,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Cai","sequence":"additional","affiliation":[{"name":"Gaoxin Branch of the First Affiliated Hospital, Jiangxi Medical College, Nanchang University Department of Pediatrics, , Nanchang ,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongping","family":"Wan","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital, Jiangxi Medical College, Nanchang University Department of Pathology, , Nanchang ,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Cai","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital, Jiangxi Medical College, Nanchang University Department of Rheumatology, , Nanchang ,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sansan","family":"Tao","sequence":"additional","affiliation":[{"name":"Jiangxi Provincial Children\u2019s Hospital Department of Nephrology, , Nanchang ,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaosi","family":"Xu","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University Department of Nephrology, , Nanchang ,","place":["P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"2026033111020396800_bib1","first-page":"Cd005128","article-title":"Interventions for preventing and treating kidney disease in Henoch-Sch\u00f6nlein Purpura (HSP)","volume":"2015","author":"Hahn","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2026033111020396800_bib2","first-page":"S26","article-title":"Henoch-Sch\u00f6nlein\u2019s purpura in adults versus children\/adolescents: a comparative study","volume":"24","author":"Uppal","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"2026033111020396800_bib3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"2026033111020396800_bib4","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/ndt\/gfae009","article-title":"Outcome of immunosuppression in children with IgA vasculitis-related nephritis","volume":"39","author":"Rohner","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026033111020396800_bib5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1358\/dot.2022.58.1.3352743","article-title":"Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus","volume":"58","author":"Fan","year":"2022","journal-title":"Drugs Today (Barc)"},{"key":"2026033111020396800_bib6","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.ekir.2024.01.003","article-title":"Effect of telitacicept on circulating Gd-IgA1 and IgA-containing immune complexes in IgA nephropathy","volume":"9","author":"Zan","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026033111020396800_bib7","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.ekir.2022.05.017","article-title":"Randomized phase II JANUS study of atacicept in patients with IgA nephropathy and persistent proteinuria","volume":"7","author":"Barratt","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2026033111020396800_bib8","doi-asserted-by":"publisher","first-page":"sfaf154","DOI":"10.1093\/ckj\/sfaf154","article-title":"Efficacy and safety of telitacicept in IgA nephropathy: real-world study outcomes","volume":"18","author":"Weng","year":"2025","journal-title":"Clin Kidney J"},{"key":"2026033111020396800_bib9","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1093\/rheumatology\/keaa104","article-title":"Gastrointestinal involvement in adult IgA vasculitis (Henoch-Sch\u00f6nlein purpura): updated picture from a French multicentre and retrospective series of 260 cases","volume":"59","author":"Audemard-Verger","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2026033111020396800_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13216621","article-title":"IgA vasculitis (Henoch-Sch\u00f6nlein purpura): an update on treatment","volume":"13","author":"Casta\u00f1eda","year":"2024","journal-title":"J Clin Med"},{"key":"2026033111020396800_bib11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2026033111020396800_bib12","doi-asserted-by":"publisher","first-page":"921864","DOI":"10.3389\/fimmu.2022.921864","article-title":"IgA vasculitis update: epidemiology, pathogenesis, and biomarkers","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"2026033111020396800_bib13","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/ndt\/gfx300","article-title":"Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort","volume":"33","author":"Berthelot","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2026033111020396800_bib14","first-page":"Cd005128","article-title":"Interventions for preventing and treating kidney disease in IgA vasculitis","volume":"2","author":"Hahn","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2026033111020396800_bib15","first-page":"728","article-title":"IgA vasculitis with nephritis: an overview of the pathogenesis and clinical characteristics","volume":"43","author":"Zhang","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"2026033111020396800_bib16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10238-024-01461-6","article-title":"The efficacy of rituximab in the treatment of IgA vasculitis nephritis","volume":"24","author":"Xiong","year":"2024","journal-title":"Clin Exp Med"},{"key":"2026033111020396800_bib17","article-title":"Disease course and long-term outcomes in adult IgA vasculitis nephritis: a prospective observational study","volume":"15","author":"Yildirim","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"2026033111020396800_bib18","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"2026033111020396800_bib19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd1982","article-title":"An APRIL to remember: novel TNF ligands as therapeutic targets","volume":"5","author":"Dillon","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"2026033111020396800_bib20","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/35010115","article-title":"TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease","volume":"404","author":"Gross","year":"2000","journal-title":"Nature"},{"key":"2026033111020396800_bib21","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.kint.2024.08.012","article-title":"Targeting APRIL in the treatment of glomerular diseases","volume":"106","author":"Cheung","year":"2024","journal-title":"Kidney Int"},{"key":"2026033111020396800_bib22","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s13730-025-00983-6","article-title":"Successful outcome of a refractory IgA vasculitis nephritis in children treated with telitacicept","volume":"14","author":"Jin","year":"2025","journal-title":"CEN Case Rep"},{"key":"2026033111020396800_bib23","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1007\/s00467-025-06769-3","article-title":"Telitacicept as a BAFF\/APRIL dual inhibitor: efficacy and safety in reducing proteinuria for refractory childhood IgA vasculitis nephritis","volume":"40","author":"Jin","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"2026033111020396800_bib24","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1007\/s00467-025-06709-1","article-title":"Telitacicept use in children with IgA vasculitis nephritis: preliminary observations","volume":"40","author":"Wang","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"2026033111020396800_bib25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026033111020396800_bib26","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1177\/09612033251332052","article-title":"Efficacy and safety of telitacicept in the treatment of systemic lupus erythematosus: a retrospective real-world study","volume":"34","author":"Zhang","year":"2025","journal-title":"Lupus"},{"key":"2026033111020396800_bib27","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrneph.2014.126","article-title":"Henoch-Sch\u00f6nlein purpura nephritis in children","volume":"10","author":"Davin","year":"2014","journal-title":"Nat Rev Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf210\/64518937\/gfaf210.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/4\/786\/64518937\/gfaf210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/4\/786\/64518937\/gfaf210.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:02:07Z","timestamp":1774969327000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/4\/786\/8275762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,10,6]]},"published-print":{"date-parts":[[2026,3,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf210","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,10,6]]}}}